NASDAQ:GOSS Gossamer Bio Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gossamer Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.46 -0.04 (-0.32 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$12.23Now: $12.46▼$12.7050-Day Range$12.50MA: $13.38▼$14.2952-Week Range$7.52Now: $12.46▼$27.15Volume352,226 shsAverage Volume528,709 shsMarket Capitalization$944.82 millionP/E RatioN/ADividend YieldN/ABeta1.17 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.57, Gossamer Bio has a forecasted upside of 145.4% from its current price of $12.46.Amount of Analyst CoverageGossamer Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesGossamer Bio has received 95 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGossamer Bio has received 103 “underperform” votes. (Add your “underperform” vote.)Community SentimentGossamer Bio has received 52.02% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Gossamer Bio and other stocks. Vote “Outperform” if you believe GOSS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GOSS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,920.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 23.30% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions68.06% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gossamer Bio are expected to grow in the coming year, from ($3.56) to ($3.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GOSS Previous Symbol CUSIPN/A CIKN/A Webwww.gossamerbio.com Phone858-922-0718Debt Debt-to-Equity Ratio0.42 Current Ratio22.09 Quick Ratio22.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book2.33Profitability EPS (Most Recent Fiscal Year)($3.29) Net Income$-180,310,000.00 Net MarginsN/A Return on Equity-60.65% Return on Assets-47.36%Miscellaneous Employees118 Outstanding Shares75,828,000Market Cap$944.82 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $12.46 -0.04 (-0.32 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GOSS News and Ratings via Email Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions How has Gossamer Bio's stock been impacted by COVID-19 (Coronavirus)? Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GOSS stock has increased by 17.7% and is now trading at $12.46. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Gossamer Bio? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gossamer Bio. When is Gossamer Bio's next earnings date? Gossamer Bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Gossamer Bio. How were Gossamer Bio's earnings last quarter? Gossamer Bio Inc (NASDAQ:GOSS) announced its earnings results on Tuesday, August, 11th. The company reported ($1.00) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.14. View Gossamer Bio's earnings history. What price target have analysts set for GOSS? 7 brokerages have issued 12 month target prices for Gossamer Bio's stock. Their forecasts range from $21.00 to $36.00. On average, they anticipate Gossamer Bio's share price to reach $30.57 in the next year. This suggests a possible upside of 145.4% from the stock's current price. View analysts' price targets for Gossamer Bio. Who are some of Gossamer Bio's key competitors? Some companies that are related to Gossamer Bio include Legend Biotech (LEGN), Reata Pharmaceuticals (RETA), Biohaven Pharmaceutical (BHVN), ChemoCentryx (CCXI), Turning Point Therapeutics (TPTX), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR), HYPERA S A/S (HYPMY), Insmed (INSM), Principia Biopharma (PRNB), Global Blood Therapeutics (GBT), TG Therapeutics (TGTX), Schrodinger (SDGR), SAGE Therapeutics (SAGE) and GW Pharmaceuticals PLC- (GWPH). View all competitors. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Alector (ALEC), Homology Medicines (FIXX), II-VI (IIVI) and Inovio Pharmaceuticals (INO). Who are Gossamer Bio's key executives? Gossamer Bio's management team includes the following people: Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)Mr. Bryan Giraudo, Chief Financial Officer (Age 43)Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)Dr. Jakob Dupont, Chief Medical Officer (Age 54) When did Gossamer Bio IPO? (GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. What is Gossamer Bio's stock symbol? Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS." Who are Gossamer Bio's major shareholders? Gossamer Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Hillhouse Capital Advisors LTD. (11.18%), Vanguard Group Inc. (7.36%), Omega Fund Management LLC (4.38%), Artal Group S.A. (4.01%), Federated Hermes Inc. (2.86%) and Alyeska Investment Group L.P. (2.25%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Fund V Gp LP Omega, Jakob Dupont, Luisa Salter-Cid, Russell J Cox and Waage Christian. View institutional ownership trends for Gossamer Bio. Which institutional investors are selling Gossamer Bio stock? GOSS stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC, FMR LLC, FMR LLC, Alps Advisors Inc., Ensign Peak Advisors Inc, and Nuveen Asset Management LLC. View insider buying and selling activity for Gossamer Bio. Which institutional investors are buying Gossamer Bio stock? GOSS stock was purchased by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Vanguard Group Inc., Alyeska Investment Group L.P., Artal Group S.A., Jennison Associates LLC, Ikarian Capital LLC, Federated Hermes Inc., and Hudson Bay Capital Management LP. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, Russell J Cox, and Waage Christian. View insider buying and selling activity for Gossamer Bio. How do I buy shares of Gossamer Bio? Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Gossamer Bio's stock price today? One share of GOSS stock can currently be purchased for approximately $12.46. How big of a company is Gossamer Bio? Gossamer Bio has a market capitalization of $944.82 million. The company earns $-180,310,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Gossamer Bio employs 118 workers across the globe. What is Gossamer Bio's official website? The official website for Gossamer Bio is www.gossamerbio.com. How can I contact Gossamer Bio? Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718. This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
